Vistagen Therapeutics, Inc. (VTGN) — 10-Q Filings
All 10-Q filings from Vistagen Therapeutics, Inc.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
Vistagen Relies on Capital Raises Amidst Zero Revenue
— Aug 7, 2025 Risk: high
Vistagen Therapeutics, Inc. reported no sublicense and other revenue for the three months ended June 30, 2025, consistent with the prior year period. The compan -
Vistagen Therapeutics Files 10-Q for Q3 2024
— Feb 13, 2025 Risk: medium
Vistagen Therapeutics, Inc. filed a 10-Q for the period ending December 31, 2024. The company, incorporated in Nevada, is in the pharmaceutical preparations ind -
Vistagen Therapeutics Reports $0 Revenue for Q2
— Nov 7, 2024 Risk: high
Vistagen Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported revenue of $0.00 for the three months ended September -
Vistagen Therapeutics Files 10-Q for Period Ending December 31, 2023
— Feb 13, 2024 Risk: medium
Vistagen Therapeutics, Inc. (VTGN) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. Vistagen Therapeutics, Inc. filed a 10-Q for the period en
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX